N/A
N=3,632
Epidemiological Study of the COVID-2019 in Participating Organizations.
Covid19
Bottom Line
View on ClinicalTrials.gov: NCT05043142 ↗Enrolled (actual)
3,632
Serious AEs
—
Results posted
Oct 2021
Primary outcome: Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- ELISA test for the antibodies to COVID-2019. (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yuria-Pharm
- Primary completion
- Jun 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Incidence of COVID-2019 Cases. |
259.95 | — |
| SECONDARY The Severity of the COVID-2019 Cases in Participating Organizations. |
55; 6; 451; 315; 65; 2551 | — |
| SECONDARY Prevention Methods of SARS, Including COVID-2019, Which Were Used by Subject That Had at Least One COVID-2019 Case. |
79; 60; 124; 1; 97; 140 | — |
| SECONDARY Prevention Methods of SARS, Including COVID-2019, Which Were Used by Subject That Did Not Have Any COVID-2019 Case. |
353; 366; 583; 4; 566; 523 | — |
| SECONDARY Relationship Between the Used Prevention Methods and and the Risk to Have at Least One Case of COVID-2019 Among Staff of Participating Organizations. |
0.875 | — |
| SECONDARY Relationship Between the Presence of Comorbidities, Such as Bronchial Asthma and COPD (Chronic Obstructive Pulmonary Disease), and the Risk to Have at Least One Case of COVID-2019. |
0.892 | — |
| SECONDARY Relationship Between the COVID-2019 Case and the Risk of Change of the Course of Comorbidities, Such as Bronchial Asthma and сhronic Obstructive Pulmonary Disease (COPD). |
0.523 | — |
| SECONDARY Relationship Between Different Strategies and Combinations of Drugs Used for Prophylactics at Any Time From March 2020 and the Risk of Having a COVID-2019 Case. |
0.949 | — |
| SECONDARY Relationship Between Different Strategies and Combinations of Drugs Used for Prophylactics at Any Time From March 2020 and the Risk of Having a Severe COVID-2019 Case. |
1.002 | — |
| SECONDARY Relationship Between Different Strategies and Combinations of Drugs Used for Prophylactics at Any Time From March 2020 and the Risk of Hospitalization of Persons Who Had at Least One COVID-2019 Case. |
0.981 | — |
Summary
Exhaustive, cross-sectional, non-interventional, multicenter retrospective epidemiological study, case study aimed to determine the relationship between the systematic use of prophylactics to prevent SARS, including COVID-2019, and the risks of incidence and serious complications of COVID-2019 among staff of participating organizations.
Eligibility Criteria
Inclusion Criteria
- The subject gave the consent to participate in the study and signed the consent to processing of personal data.
- The subject aged 18 years and older.
- The subject is employed by one of the participating organizations.
Exclusion Criteria
The subject may not be included in the study due to non-compliance with the inclusion criteria or due to force majeure.
Data sourced from ClinicalTrials.gov (NCT05043142). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.